The Food and Drug Administration warned last week that the risk of heart attack and stroke from widely used painkillers that include Motrin IB, Aleve and Celebrex but not aspirin was greater than it previously had said. But what does that mean for people who take them?
Experts said that the warning reflected the gathering evidence that there was risk even in small amounts of the drug, so-called nonaspirin, nonsteroidal anti-inflammatory drugs, or Nsaids, and that everyone taking them should use them sparingly for brief periods. Millions of Americans take them.
“One of the underlying messages for this warning has to be there are no completely safe pain relievers, period,” said Bruce Lambert, director of the Center for Communication and Health at Northwestern University, who specializes in drug safety communication.
Essential oils are used in aromatherapy and may provide numerous health benefits. These oils are starting to be explored by the scientific community for their effectiveness in treating cancer, HIV, asthma, bronchitis, heart disease and strokes.
It appears that the FDA is not too happy about this healing potential. This past week, Young Living and doTERRA both received letters from the FDA claiming that their products are being marketed as unapproved drugs. The companies are being told that they have to remove all health claims and take corrective actions or they face serious legal consequences. Considering past FDA threats, these consequences would most likely look like armed federal marshals ransacking their warehouses and seizing all of their products.
FDA sends letters to Young Living and doTerra claiming their products are being marketed as unapproved drugs
It is not the first time that the FDA has gone after companies that sell holistic products. The FDA has issued warning letters to producers of walnuts, cranberries, elderberry juice, and coconut oil. Both of these essential oil companies are network-based marketing companies, which provides a unique challenge for the companies as well as the FDA. The FDA reports that the independent distributors are “paid consultants,” therefore, the parent companies have control over how their products are being marketed by the consultants.